Retinoblastoma - Pipeline Review, H2 2011

Global Markets Direct, October 2011, Pages: 57

Retinoblastoma - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Retinoblastoma - Pipeline Review, H2 2011', provides an overview of the Retinoblastoma therapeutic pipeline. This report provides information on the therapeutic development for Retinoblastoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Retinoblastoma. 'Retinoblastoma - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Retinoblastoma.
- A review of the Retinoblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Retinoblastoma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Retinoblastoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Retinoblastoma pipeline depth and focus of Retinoblastoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoblastoma Overview
Therapeutics Development
An Overview of Pipeline Products for Retinoblastoma
Retinoblastoma Therapeutics under Development by Companies
Retinoblastoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Retinoblastoma Therapeutics - Products under Development by Companies
Retinoblastoma Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Retinoblastoma Therapeutics Development
RXi Pharmaceuticals Corporation
Neotropix, Inc.
Retinoblastoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
NTX-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Amifostine Trihydrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Becatecarin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Torisel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melphalan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Cyclosporine + Etoposide + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Topotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Carboplatin + Topotecan + Etoposide + Filgrastim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Carboplatin + Filgrastim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Carboplatin + Etoposide + Stem Cell Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Etoposide + Vincristine + Filgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Cyclophosphamide + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IMC-A12 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinal Disorder Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Cyclophosphamide + Doxorubicin + Carboplatin + Etoposide + Filgrastim + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Melphalan Hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Retinoblastoma Therapeutics – Drug Profile Updates
Retinoblastoma Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Retinoblastoma - Pipeline Review, Q1 2011
• Retinoblastoma - Pipeline Review, Q4 2010
• Brain Cancer - Pipeline Review, H2 2012
• Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, H2 2012
• Neurofibromatoses - Pipeline Review, H2 2012
• Other Hematological Disorders - Pipeline Review, H2 2012
• Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012
• Thrombocytopenia - Pipeline Review, H2 2012
• Amyloidosis - Pipeline Review, H2 2012
• Primary Systemic Amyloidosis - Pipeline Review, H2 2012